Imugene Limited
IUGNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $113 | $257 | $446 | $606 |
| - Cash | $22 | $34 | $93 | $139 |
| + Debt | $11 | $16 | $2 | $6 |
| Enterprise Value | $102 | $239 | $355 | $473 |
| Revenue | $3 | $1 | -$3 | $8 |
| % Growth | 149.5% | 140.6% | -138.4% | – |
| Gross Profit | $3 | $1 | -$3 | $8 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$19 | -$49 | -$77 | -$69 |
| % Margin | -602.3% | -3,857.1% | 2,495.3% | -857.1% |
| Net Income | -$21 | -$48 | -$81 | -$69 |
| % Margin | -659% | -3,842.5% | 2,613.5% | -851.7% |
| EPS Diluted | -0.094 | -0.22 | -0.38 | -0.34 |
| % Growth | 57.2% | 42.1% | -11.8% | – |
| Operating Cash Flow | -$37 | -$39 | -$49 | -$48 |
| Capital Expenditures | $3 | -$11 | $2 | -$11 |
| Free Cash Flow | -$34 | -$49 | -$47 | -$60 |